Strongbridge Biopharma plc (SBBP)
SBBPPrice: $2
Fair Value: 🔒
🔒score
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of... more
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Matthew Pauls |
| IPO Date | 2015-09-10 | CAGR | — |
| Employees | 72 | Website | www.strongbridgebio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SBBP chart loading...
Fundamentals
Technicals
| Enterprise Value | $155.30M | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 1.71 |
| P/CF Ratio | -2.94 | P/FCF Ratio | — |
| EPS | — | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 34.98% | Gross Margin | 0.93% |
| Operating Margin | -1.4% | Profit Margin | -1.47% |
| ROE | -0.65% | ROA | -0.37% |
| ROCE | -0.43% | Current Ratio | 4.37 |
| Quick Ratio | 4.32 | Cash Ratio | 4.14 |
| Debt/Equity | 0.28 | Interest Coverage | -32.31 |
| Altman Z Score | — | Piotroski Score | — |